Latest news

Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

Debiopharm’s New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer

Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program

Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…